Solid Biosciences Inc.
SLDB
$5.10
-$0.12-2.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.58% | 19.83% | 21.54% | 19.98% | 30.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.39% | 56.78% | 44.15% | 24.36% | 5.66% |
| Operating Income | -51.39% | -56.78% | -44.15% | -24.36% | -5.66% |
| Income Before Tax | -63.16% | -69.90% | -54.77% | -29.87% | -12.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.16% | -69.90% | -54.77% | -29.87% | -12.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.16% | -69.90% | -54.77% | -29.87% | -12.78% |
| EBIT | -51.39% | -56.78% | -44.15% | -24.36% | -5.66% |
| EBITDA | -52.88% | -58.84% | -44.85% | -25.10% | -6.53% |
| EPS Basic | 18.08% | 15.20% | 24.08% | 37.27% | 40.94% |
| Normalized Basic EPS | 18.08% | 15.20% | 24.14% | 37.31% | 47.78% |
| EPS Diluted | 18.08% | 15.20% | 24.08% | 37.31% | 40.98% |
| Normalized Diluted EPS | 18.08% | 15.20% | 24.14% | 37.31% | 47.78% |
| Average Basic Shares Outstanding | 111.42% | 104.91% | 95.11% | 105.27% | 98.89% |
| Average Diluted Shares Outstanding | 111.42% | 104.91% | 95.11% | 105.27% | 98.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |